|
|
|
PCVX Description — Vaxcyte Inc
Vaxcyte is a clinical-stage vaccine company. Co. is developing conjugate and protein vaccines to treat bacterial infectious diseases. Co.'s primary vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine (PCV) for the treatment of invasive pneumococcal disease and pneumonia. Co.'s second PCV candidate, VAX-XP, is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition, Co.'s pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep and VAX-PG, a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis.
Company Name: |
Vaxcyte Inc |
Website: |
www.vaxcyte.com |
Sector: |
Biotechnology |
Number of ETFs Holding PCVX: |
33 |
Total Market Value Held by ETFs: |
$931,827,775.2 |
Total Market Capitalization: |
$3,123,000,000 |
% of Market Cap. Held by ETFs: |
29.84% |
|
ETF |
PCVX Weight |
PCVX Amount |
VTI |
0.01% |
$200,700,100 |
IWM |
0.27% |
$163,499,259 |
VB |
0.11% |
$161,147,450 |
VXF |
0.09% |
$95,124,300 |
VBK |
0.26% |
$91,226,478 |
XBI |
0.97% |
$64,973,740 |
IWO |
0.53% |
$58,327,658 |
VTWO |
0.26% |
$25,805,168 |
VHT |
0.10% |
$20,007,990 |
PDP |
0.57% |
$6,990,306 |
List of all 33 ETFs holding PCVX
» |
|
|
|
|
Strong Buy (3.89 out of 4)
75th percentile
|
PARTNER NEWS:Wed, Feb 28, 11:00 AM, Zacks
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Mon, Feb 26, 6:38 AM, Zacks
5 Stocks to Buy That Are Poised to Beat on Earnings This Week We have narrowed our search to five stocks that are poised to beat on earnings this week. These are HEi, CEG, IPAR, APLS, PCVX.
|
|